Labcorp’s chief accounting officer sells $347,738 in stock

Peter J. Wilkinson, the Senior Vice President and Chief Accounting Officer at Labcorp Holdings Inc. (NYSE:LH), a prominent $20.7 billion healthcare services provider with a "GOOD" InvestingPro Financial Health rating, recently sold shares of the company’s stock. According to a filing with the Securities and Exchange Commission, Wilkinson sold 1,413 shares on February 18, 2025, at an average price of $246.10 per share, totaling approximately $347,738.

On the same day, Wilkinson acquired 1,413 shares through the exercise of stock options at a price of $163.63 per share, which amounted to a transaction value of $231,209. Following these transactions, Wilkinson holds 1,993.2194 shares of Labcorp directly. The stock is currently trading near its 52-week high of $258.59, showing strong momentum with a 16.4% return over the past year.

Additionally, a prior transaction on August 1, 2022, involved a charitable donation of 351 shares to a donor-advised fund, which did not involve any cash exchange. According to InvestingPro, the company’s management has been actively buying back shares, and the stock maintains relatively low price volatility. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.

In other recent news, Laboratory Corporation of America reported robust fourth-quarter earnings and revenues, surpassing analysts’ expectations. Jefferies analyst Tycho Peterson noted the company’s strong financial results and increased the stock price target to $290, maintaining a Buy rating. Similarly, Truist Securities raised its price target to $285, also affirming a Buy rating, citing strong core business momentum and promising guidance for 2025. Evercore ISI upgraded Labcorp’s stock to Outperform, with a new price target of $265, highlighting potential growth in earnings and diagnostic margins.

Labcorp also announced the expansion of its credit facility to $700 million, enhancing its financial flexibility. Additionally, the company released a new H5 bird flu molecular test in collaboration with the CDC, aiming to improve public health preparedness during the ongoing outbreak. The test is available across the United States, except in New York State, and emphasizes Labcorp’s commitment to supporting healthcare providers with essential diagnostic tools. These developments reflect Labcorp’s strategic initiatives in diagnostics and financial management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.